Cargando…

Longitudinal expression changes are weak correlates of disease progression in Huntington’s disease

Huntington’s disease is a severe but slowly progressive hereditary illness for which only symptomatic treatments are presently available. Clinical measures of disease progression are somewhat subjective and may require years to detect significant change. There is a clear need to identify more sensit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitchell, Christopher T, Krier, Irina, Arjomand, Jamshid, Borowsky, Beth, Tabrizi, Sarah J, Leavitt, Blair R, Luthi-Carter, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713990/ https://www.ncbi.nlm.nih.gov/pubmed/33305259 http://dx.doi.org/10.1093/braincomms/fcaa172

Ejemplares similares

A Computational Cognitive Biomarker for Early-Stage Huntington’s Disease
por: Wiecki, Thomas V., et al.
Publicado: (2016)

Testing a longitudinal compensation model in premanifest Huntington’s disease
por: Gregory, Sarah, et al.
Publicado: (2018)

Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease
por: Minkova, Lora, et al.
Publicado: (2017)

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study
por: Klöppel, Stefan, et al.
Publicado: (2015)

Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease
por: McColgan, Peter, et al.
Publicado: (2017)

Progressive alterations in white matter microstructure across the timecourse of Huntington's disease
por: Estevez‐Fraga, Carlos, et al.
Publicado: (2023)

Potential biomarkers to follow the progression and treatment response of Huntington’s disease
por: Disatnik, Marie-Hélène, et al.
Publicado: (2016)

Preface to the Special Issue on “Sleep and Circadian Disorder in Huntington’s Disease”
por: Leavitt, Blair R., et al.
Publicado: (2023)

Novel Metabolic Abnormalities in the Tricarboxylic Acid Cycle in Peripheral Cells From Huntington’s Disease Patients
por: Naseri, Nima N., et al.
Publicado: (2016)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Altered Intracortical T(1)-Weighted/T(2)-Weighted Ratio Signal in Huntington’s Disease
por: Rowley, Christopher D., et al.
Publicado: (2018)

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease
por: Stout, Julie C, et al.
Publicado: (2012)

Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
por: Mazarei, Gelareh, et al.
Publicado: (2015)

Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling
por: Minkova, Lora, et al.
Publicado: (2015)

Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation
por: Seredenina, Tamara, et al.
Publicado: (2011)

Natural biological variation of white matter microstructure is accentuated in Huntington's disease
por: Gregory, Sarah, et al.
Publicado: (2018)

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington’s Disease
por: Johnson, Eileanoir B., et al.
Publicado: (2017)

Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington’s disease models
por: Smalley, Joshua L., et al.
Publicado: (2015)

Overlap between age-at-onset and disease-progression determinants in Huntington disease
por: Aziz, N. Ahmad, et al.
Publicado: (2018)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY
por: Orth, Michael, et al.
Publicado: (2011)

Computational deconvolution of genome wide expression data from Parkinson's and Huntington's disease brain tissues using population-specific expression analysis
por: Capurro, Alberto, et al.
Publicado: (2015)

Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories
por: Ross, Christopher A., et al.
Publicado: (2019)

Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models
por: Träger, Ulrike, et al.
Publicado: (2015)

Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration
por: Estevez-Fraga, Carlos, et al.
Publicado: (2023)

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
por: Byrne, Lauren M, et al.
Publicado: (2017)

Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects
por: Abreu, Daisy, et al.
Publicado: (2021)

Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington’S Disease Model
por: Landles, Christian, et al.
Publicado: (2020)

Brain Regions Showing White Matter Loss in Huntington’s Disease Are Enriched for Synaptic and Metabolic Genes
por: McColgan, Peter, et al.
Publicado: (2018)

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
por: Bénard, Angèle, et al.
Publicado: (2022)

Assessment of Cognitive Symptoms in Prodromal and Early Huntington Disease
por: Vaccarino, Anthony L, et al.
Publicado: (2011)

A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington’s disease
por: Collins, Lucy M, et al.
Publicado: (2014)

Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study
por: Baake, Verena, et al.
Publicado: (2018)

Sleep deficits but no metabolic deficits in premanifest Huntington's disease
por: Lazar, Alpar S., et al.
Publicado: (2015)

Genome-Wide Histone Acetylation Is Altered in a Transgenic Mouse Model of Huntington's Disease
por: McFarland, Karen N., et al.
Publicado: (2012)

Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity
por: Caron, Nicholas S, et al.
Publicado: (2022)

Diffusion imaging in Huntington’s disease: comprehensive review
por: Estevez-Fraga, Carlos, et al.
Publicado: (2021)

Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington’s disease
por: Liu, Chin-Fu, et al.
Publicado: (2023)

MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington’s Disease-Related Mechanisms
por: Jovicic, Ana, et al.
Publicado: (2013)

Huntington’s Disease Clinical Trials Corner: August 2023
por: Estevez-Fraga, Carlos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_073t7cns3v8kh3jtpbc2orb8jo